Developer docs
API playgroundTry for free, no card

Search company profiles

MEGGLE

Full company profile

uuid000wy6j

Namestring
MEGGLE
Legal namestring
MEGGLE GmbH & Co. KG
Company typeenum
Private
Founded yearint
1887
Descriptiontext

MEGGLE is a German family-owned pharmaceutical excipient manufacturer headquartered in Bruckmühl, Bavaria, with a secondary production facility in the USA. Founded in 1887, the company has produced lactose and co-processed excipients for over 75 years and supplies pharmaceutical manufacturers across 110 countries. Its product portfolio is organized into five categories — sieved lactose, milled lactose, direct compression lactose (agglomerated, spray-dried, anhydrous), co-processed excipients (Cellactose 80, MicroceLac 100, StarLac, RetaLac, CombiLac, MicroceLac Plus), and dry powder inhalation (DPI) lactose grades — supported by specialized offerings such as Lactose Monohydrate Low Endotoxin and Compaction Blend M.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersWasserburg, Germany
HQ citystring
Wasserburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical excipients, lactose manufacturing, direct compression excipients, dry powder inhalation lactose, co-processed excipients
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Food And Kindred Products2000
Product category
Pharmaceutical Excipients
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Excipients Sales
TypeOne Time License
Description

B2B sales of pharmaceutical-grade lactose and co-processed excipients to pharmaceutical manufacturers for tablet, capsule, powder formulation, and inhalation applications

meggle-excipients.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1B2B pharmaceutical excipients with quote-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed

meggle-excipients.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MEGGLE manufactures and sells pharmaceutical-grade lactose and co-processed excipients for tablet, capsule, powder formulation, and dry powder inhalation (DPI) applications. The company operates two state-of-the-art production facilities in Germany and the USA and supplies its excipients to pharmaceutical manufacturers across 110 countries, supported by a global network of application laboratories (ExciLabs) and technical advisors.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

MEGGLE Excipients is a pharmaceutical excipient company with over 70 years of experience producing high-quality lactose and co-processed excipients for tablets, capsules, powder formulations, and dry powder inhalation (DPI) applications. The product portfolio is organized into five main lactose categories: (1) Sieved Lactose (PrismaLac 40, CapsuLac 60, SacheLac 80, SpheroLac 100); (2) Milled Lactose (GranuLac 70/70 US, 80, 140/140 US, 200/200 US/200 Low Nitrite, 230/230 Low Nitrite, SorboLac 400); (3) Direct Compression (DC) lactose including agglomerated (Tablettose 70, 80, 100/100 Low Nitrite), spray-dried (FlowLac 90, 100/100 Low Nitrite), anhydrous (DuraLac H), and co-processed excipients (Cellactose 80, MicroceLac 100, MicroceLac Plus, CombiLac, StarLac, RetaLac); (4) DPI lactose grades spanning sieved (InhaLac 70, 120, 160, 230, 240, 251), milled (InhaLac 140, 145, 150, 180), and fine milled variants (InhaLac 300, 400, 500); and (5) Special Applications including Lactose Monohydrate Low Endotoxin and Compaction Blend M. Complementing the product portfolio are digital tools including the Product Configurator, Nitrosamine Risk Assessment Calculator, DPI Blend Prediction Tool, and DPI Selection Guide, supported by ExciLabs application laboratories and DPI customization services. MEGGLE operates two production facilities in Germany and the USA and supplies to over 110 countries.

Product and service9 records
1Sieved Lactose (PrismaLac 40, CapsuLac 60, SacheLac 80, SpheroLac 100)
CategoryPharmaceutical Excipients - Lactose
Description

Sieved lactose excipients produced through sieving processes to achieve precise particle size distribution, used by pharmaceutical manufacturers in tablet and capsule formulations.

2Milled Lactose (GranuLac 70, 80, 140, 200, 230, SorboLac 400)
CategoryPharmaceutical Excipients - Lactose
Description

Milled lactose excipients offering varied particle size distributions for tablet and capsule formulations, including US pharmacopeia-compliant variants.

3Direct Compression Lactose (Tablettose, FlowLac, DuraLac H)
CategoryPharmaceutical Excipients - Lactose
Description

Lactose excipients including agglomerated (Tablettose 70, 80, 100), spray-dried (FlowLac 90, 100), and anhydrous (DuraLac H) grades engineered for direct compression tablet manufacturing.

4Co-processed Excipients (Cellactose 80, MicroceLac 100, MicroceLac Plus, CombiLac, StarLac, RetaLac)
CategoryPharmaceutical Excipients - Co-processed
Description

Advanced lactose-based co-processed excipients combining lactose with cellulose, microcrystalline cellulose, starch or other excipients to deliver enhanced functional properties for tablet and capsule formulations.

5Dry Powder Inhalation Lactose (InhaLac 70, 120, 140, 145, 150, 160, 180, 230, 240, 251, 300, 400, 500)
CategoryPharmaceutical Excipients - Inhalation
Description

Inhalation-grade lactose excipients in sieved, milled, and fine milled grades with controlled particle sizes for dry powder inhaler (DPI) formulations.

6Special Application Lactose (Lactose Monohydrate Low Endotoxin, Compaction Blend M)
CategoryPharmaceutical Excipients - Specialty
Description

Specialized lactose excipients including low endotoxin lactose monohydrate and Compaction Blend M for sensitive pharmaceutical and specialized compaction applications.

7MEGGLE Low Nitrite Lactose Grades
CategoryPharmaceutical Excipients - Lactose
Description

New premium lactose grades with controlled low nitrite levels developed using ion chromatography to minimize nitrosamine formation risk in pharmaceutical formulations.

8ExciLabs Application Laboratories
CategoryApplication Services
Description

MEGGLE's global network of application laboratories where expert teams provide formulation support and turn formulation challenges into excipient solutions for pharmaceutical manufacturers.

9DPI Customized Lactose
CategoryApplication Services
Description

Customization service that tailors inhalation-grade lactose to meet the exact particle size and blending ratio requirements of dry powder inhaler (DPI) development projects.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US specialty company providing pharmaceutical excipients, coatings, and formulation aids. Colorcon competes with MEGGLE in direct compression excipients, controlled-release coatings, and DPI formulation support, addressing overlapping pharmaceutical manufacturer customers.

TypeBroad incumbent
Description

German chemical giant with broad pharmaceutical excipient portfolio serving pharma manufacturers globally. While not specialized in lactose, BASF's pharma ingredients business overlaps with MEGGLE's excipient offerings as part of a much larger diversified portfolio.

TypeDirect peer
Description

French global leader in starches, polyols, and pharmaceutical excipients. Roquette competes directly with MEGGLE in pharmaceutical lactose, cyclodextrins, and co-processed excipients for tablet and capsule formulations, with comparable global manufacturing footprint and customer base.

TypeDirect peer
Description

US-based manufacturer and distributor of pharmaceutical ingredients, excipients, and high-purity materials. Avantor's pharmaceutical excipient portfolio overlaps materially with MEGGLE's offerings, serving similar pharmaceutical customers across formulation and DPI applications.

TypeDirect peer
Description

Dutch pharmaceutical excipient manufacturer specializing in lactose, co-processed excipients, and inhalation-grade products. DFE Pharma is the most direct competitor to MEGGLE, serving the same pharmaceutical customers with overlapping product portfolios across oral solid dose and DPI applications.

TypeBroad incumbent
Description

German life science company with significant pharmaceutical ingredients and excipients business through its Life Science sector. Operates broadly across pharma materials, bioprocessing, and lab products with partial overlap to MEGGLE's excipient portfolio.

TypeDirect peer
Description

Specialty pharmaceutical excipient manufacturer with portfolio including antacid actives, co-processed excipients, and direct compression systems. SPI Pharma competes with MEGGLE in co-processed excipients for oral solid dose formulations, serving similar pharmaceutical customers.

TypeBroad incumbent
Description

Large ingredient company with pharmaceutical excipient offerings as part of broader food and beverage portfolio. IFF's pharma excipient business overlaps with MEGGLE in select biopolymers and formulation aids but lacks MEGGLE's focus on pharmaceutical lactose.

TypeBroad incumbent
Description

Irish multinational with pharmaceutical and food ingredient divisions. Kerry's pharmaceutical excipient offerings overlap with MEGGLE in select categories as part of a broader taste, nutrition, and ingredient portfolio rather than as a focused pharmaceutical excipient specialist.

TypeOthers
Description

Dutch specialty chemicals and ingredients distributor representing multiple pharmaceutical excipient manufacturers. IMCD serves as a complementary distribution channel and ecosystem participant for pharma excipients rather than a direct manufacturing competitor to MEGGLE.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MEGGLE

Pharmaceutical Excipientsmeggle-pharma.com

What MEGGLE does

MEGGLE is a German family-owned pharmaceutical excipient manufacturer headquartered in Bruckmühl, Bavaria, with a secondary production facility in the USA. Founded in 1887, the company has produced lactose and co-processed excipients for over 75 years and supplies pharmaceutical manufacturers across 110 countries. Its product portfolio is organized into five categories — sieved lactose, milled lactose, direct compression lactose (agglomerated, spray-dried, anhydrous), co-processed excipients (Cellactose 80, MicroceLac 100, StarLac, RetaLac, CombiLac, MicroceLac Plus), and dry powder inhalation (DPI) lactose grades — supported by specialized offerings such as Lactose Monohydrate Low Endotoxin and Compaction Blend M.

MEGGLE firmographics

Firmographics
Name
MEGGLE
Legal name
MEGGLE GmbH & Co. KG
Website
https://meggle-pharma.com
Company type
Private
Founded year
1887
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Where MEGGLE is headquartered

Location

Headquarters

HQ city
Wasserburg
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

MEGGLE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Excipients Sales: B2B sales of pharmaceutical-grade lactose and co-processed excipients to pharmaceutical manufacturers for tablet, capsule, powder formulation, and inhalation applications

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B pharmaceutical excipients with quote-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

MEGGLE product offering

Product offering

Core offering

MEGGLE manufactures and sells pharmaceutical-grade lactose and co-processed excipients for tablet, capsule, powder formulation, and dry powder inhalation (DPI) applications. The company operates two state-of-the-art production facilities in Germany and the USA and supplies its excipients to pharmaceutical manufacturers across 110 countries, supported by a global network of application laboratories (ExciLabs) and technical advisors.

Product overview

MEGGLE Excipients is a pharmaceutical excipient company with over 70 years of experience producing high-quality lactose and co-processed excipients for tablets, capsules, powder formulations, and dry powder inhalation (DPI) applications. The product portfolio is organized into five main lactose categories: (1) Sieved Lactose (PrismaLac 40, CapsuLac 60, SacheLac 80, SpheroLac 100); (2) Milled Lactose (GranuLac 70/70 US, 80, 140/140 US, 200/200 US/200 Low Nitrite, 230/230 Low Nitrite, SorboLac 400); (3) Direct Compression (DC) lactose including agglomerated (Tablettose 70, 80, 100/100 Low Nitrite), spray-dried (FlowLac 90, 100/100 Low Nitrite), anhydrous (DuraLac H), and co-processed excipients (Cellactose 80, MicroceLac 100, MicroceLac Plus, CombiLac, StarLac, RetaLac); (4) DPI lactose grades spanning sieved (InhaLac 70, 120, 160, 230, 240, 251), milled (InhaLac 140, 145, 150, 180), and fine milled variants (InhaLac 300, 400, 500); and (5) Special Applications including Lactose Monohydrate Low Endotoxin and Compaction Blend M. Complementing the product portfolio are digital tools including the Product Configurator, Nitrosamine Risk Assessment Calculator, DPI Blend Prediction Tool, and DPI Selection Guide, supported by ExciLabs application laboratories and DPI customization services. MEGGLE operates two production facilities in Germany and the USA and supplies to over 110 countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sieved Lactose (PrismaLac 40, CapsuLac 60, SacheLac 80, SpheroLac 100) Sieved lactose excipients produced through sieving processes to achieve precise particle size distribution, used by pharmaceutical manufacturers in tablet and capsule formulations.
  • Milled Lactose (GranuLac 70, 80, 140, 200, 230, SorboLac 400) Milled lactose excipients offering varied particle size distributions for tablet and capsule formulations, including US pharmacopeia-compliant variants.
  • Direct Compression Lactose (Tablettose, FlowLac, DuraLac H) Lactose excipients including agglomerated (Tablettose 70, 80, 100), spray-dried (FlowLac 90, 100), and anhydrous (DuraLac H) grades engineered for direct compression tablet manufacturing.
  • Co-processed Excipients (Cellactose 80, MicroceLac 100, MicroceLac Plus, CombiLac, StarLac, RetaLac) Advanced lactose-based co-processed excipients combining lactose with cellulose, microcrystalline cellulose, starch or other excipients to deliver enhanced functional properties for tablet and capsule formulations.
  • Dry Powder Inhalation Lactose (InhaLac 70, 120, 140, 145, 150, 160, 180, 230, 240, 251, 300, 400, 500) Inhalation-grade lactose excipients in sieved, milled, and fine milled grades with controlled particle sizes for dry powder inhaler (DPI) formulations.
  • Special Application Lactose (Lactose Monohydrate Low Endotoxin, Compaction Blend M) Specialized lactose excipients including low endotoxin lactose monohydrate and Compaction Blend M for sensitive pharmaceutical and specialized compaction applications.
  • MEGGLE Low Nitrite Lactose Grades New premium lactose grades with controlled low nitrite levels developed using ion chromatography to minimize nitrosamine formation risk in pharmaceutical formulations.
  • ExciLabs Application Laboratories MEGGLE's global network of application laboratories where expert teams provide formulation support and turn formulation challenges into excipient solutions for pharmaceutical manufacturers.
  • DPI Customized Lactose Customization service that tailors inhalation-grade lactose to meet the exact particle size and blending ratio requirements of dry powder inhaler (DPI) development projects.

Companies that use MEGGLE

Customer profile

Segments1 record

Ideal customer profiles1 record

MEGGLE technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MEGGLE partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

MEGGLE competitors and assessment

Company assessment

Direct peers

  • Colorcon: US specialty company providing pharmaceutical excipients, coatings, and formulation aids. Colorcon competes with MEGGLE in direct compression excipients, controlled-release coatings, and DPI formulation support, addressing overlapping pharmaceutical manufacturer customers.
  • Roquette: French global leader in starches, polyols, and pharmaceutical excipients. Roquette competes directly with MEGGLE in pharmaceutical lactose, cyclodextrins, and co-processed excipients for tablet and capsule formulations, with comparable global manufacturing footprint and customer base.
  • Avantor: US-based manufacturer and distributor of pharmaceutical ingredients, excipients, and high-purity materials. Avantor's pharmaceutical excipient portfolio overlaps materially with MEGGLE's offerings, serving similar pharmaceutical customers across formulation and DPI applications.
  • DFE Pharma: Dutch pharmaceutical excipient manufacturer specializing in lactose, co-processed excipients, and inhalation-grade products. DFE Pharma is the most direct competitor to MEGGLE, serving the same pharmaceutical customers with overlapping product portfolios across oral solid dose and DPI applications.
  • SPI Pharma: Specialty pharmaceutical excipient manufacturer with portfolio including antacid actives, co-processed excipients, and direct compression systems. SPI Pharma competes with MEGGLE in co-processed excipients for oral solid dose formulations, serving similar pharmaceutical customers.

Broad incumbents

  • BASF: German chemical giant with broad pharmaceutical excipient portfolio serving pharma manufacturers globally. While not specialized in lactose, BASF's pharma ingredients business overlaps with MEGGLE's excipient offerings as part of a much larger diversified portfolio.
  • Merck KGaA (Life Science): German life science company with significant pharmaceutical ingredients and excipients business through its Life Science sector. Operates broadly across pharma materials, bioprocessing, and lab products with partial overlap to MEGGLE's excipient portfolio.
  • IFF (DuPont Nutrition & Biosciences): Large ingredient company with pharmaceutical excipient offerings as part of broader food and beverage portfolio. IFF's pharma excipient business overlaps with MEGGLE in select biopolymers and formulation aids but lacks MEGGLE's focus on pharmaceutical lactose.
  • Kerry Group: Irish multinational with pharmaceutical and food ingredient divisions. Kerry's pharmaceutical excipient offerings overlap with MEGGLE in select categories as part of a broader taste, nutrition, and ingredient portfolio rather than as a focused pharmaceutical excipient specialist.

Others

  • IMCD: Dutch specialty chemicals and ingredients distributor representing multiple pharmaceutical excipient manufacturers. IMCD serves as a complementary distribution channel and ecosystem participant for pharma excipients rather than a direct manufacturing competitor to MEGGLE.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

MEGGLE social profiles

Digital presence

MEGGLE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MEGGLE leadership team

Management profile

Number of profiles

Profiles2 records

MEGGLE funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MEGGLE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEGGLE

What does MEGGLE do?

MEGGLE manufactures and sells pharmaceutical-grade lactose and co-processed excipients for tablet, capsule, powder formulation, and dry powder inhalation (DPI) applications. The company operates two state-of-the-art production facilities in Germany and the USA and supplies its excipients to pharmaceutical manufacturers across 110 countries, supported by a global network of application laboratories (ExciLabs) and technical advisors.

Is MEGGLE a public or private company?

MEGGLE is a private company. It is classified as family owned and is currently operating.

When was MEGGLE founded?

MEGGLE was founded in 1887. It employs 1,001 to 5,000 people.

Where is MEGGLE based?

MEGGLE is headquartered in Wasserburg, Germany, in the Europe region.

How does MEGGLE make money?

One revenue line is on record: pharmaceutical Excipients Sales.

Who are MEGGLE's main competitors?

Direct peers on record are Colorcon, Roquette, Avantor, DFE Pharma and SPI Pharma. Broad incumbents are BASF, Merck KGaA (Life Science), IFF (DuPont Nutrition & Biosciences) and Kerry Group. IMCD is listed as an others.

Does MEGGLE have an API?

No public API is recorded for MEGGLE.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Precedence ResearchUS Pharmaceutical Excipients Market Size to Hit USD 5.58 Billion by 2035The US pharmaceutical excipients market is projected to grow from USD 3.08 billion in 2025 to USD 5.58 billion by 2035, expanding at a compound annual growth rate of 6.12%. This expansion is primarily driven by increasing demand for biologics, specialty drugs, and advanced formulations requiring high-performance ingredients, alongside the integration of artificial intelligence in drug development. Key industry players such as DFE Pharma, MEGGLE Pharma, Roquette, and Evonik are actively investing in capacity expansion and technological innovation to meet these rising requirements.PR NewswireLBB Specialties Announces Strategic Partnership With MEGGLE On US Distribution Of Excipient ProductsLBB Specialties announced a strategic partnership with MEGGLE Excipients & Technology to distribute MEGGLE's excipient products in the US, effective August 1, 2019. Its subsidiaries AIC and Charkit will handle sales and marketing. MEGGLE, a lactose excipient manufacturer, cited the partners' industry knowledge as a key factor.PR NewswireLBB Specialties Announces Strategic Partnership With MEGGLE On US Distribution Of Excipient ProductsLBB Specialties LLC, through its subsidiaries American International Chemical and Charkit Chemical Company, entered into a strategic partnership with MEGGLE Excipients & Technology effective August 1, 2019, to distribute MEGGLE's pharmaceutical excipient products to the US pharmaceutical and nutraceutical industries. MEGGLE, one of only a handful of global manufacturers of pharma-grade lactose excipients, selected the US-based distributors for their industry knowledge and sales capabilities to more effectively serve the American market. The partnership combines MEGGLE's technical expertise and product portfolio with LBB Specialties' distribution network, creating a unified approach to serving US customers.